Cymabay Therapeu

Company Profile

Cymabay Therapeu had its IPO on 2014-02-03 under the ticker symbol CBAY.

The company operates in the Healthcare sector and Biotechnology industry. Cymabay Therapeu has a staff strength of 60 employees.

Stock update

Shares of Cymabay Therapeu opened at $18 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $17.18 - $18.2, and closed at $17.62.

This is a +2.86% increase from the previous day's closing price.

A total volume of 5,907,877 shares were traded at the close of the day’s session.

In the last one week, shares of Cymabay Therapeu have increased by +24.26%.

Cymabay Therapeu's Key Ratios

Cymabay Therapeu has a market cap of $926.38 million, indicating a price to book ratio of 5.7554 and a price to sales ratio of 0.

In the last 12-months Cymabay Therapeu’s revenue was $0 with a gross profit of $-41635000 and an EBITDA of $-94744000. The EBITDA ratio measures Cymabay Therapeu's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Cymabay Therapeu’s operating margin was 0% while its return on assets stood at -26.76% with a return of equity of -101.16%.

In Q1, Cymabay Therapeu’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Cymabay Therapeu’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

0

Its diluted EPS in the last 12-months stands at $-1.26 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cymabay Therapeu’s profitability.

Cymabay Therapeu stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -3.0321. Its price to sales ratio in the trailing 12-months stood at 0.

Cymabay Therapeu stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$245.32 million

Total Liabilities

$46.50 million

Operating Cash Flow

$-60642000.00

Capital Expenditure

$195000

Dividend Payout Ratio

0%

Cymabay Therapeu ended 2024 with $245.32 million in total assets and $0 in total liabilities. Its intangible assets were valued at $245.32 million while shareholder equity stood at $104.19 million.

Cymabay Therapeu ended 2024 with $0 in deferred long-term liabilities, $46.50 million in other current liabilities, 17000.00 in common stock, $-901635000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $59.15 million and cash and short-term investments were $236.37 million. The company’s total short-term debt was $537,000 while long-term debt stood at $94.63 million.

Cymabay Therapeu’s total current assets stands at $242.72 million while long-term investments were $0 and short-term investments were $177.22 million. Its net receivables were $1.73 million compared to accounts payable of $1.63 million and inventory worth $0.

In 2024, Cymabay Therapeu's operating cash flow was $-60642000.00 while its capital expenditure stood at $195000.

Comparatively, Cymabay Therapeu paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$17.62

52-Week High

$11.22

52-Week Low

$1.81

Analyst Target Price

$13.5

Cymabay Therapeu stock is currently trading at $17.62 per share. It touched a 52-week high of $11.22 and a 52-week low of $11.22. Analysts tracking the stock have a 12-month average target price of $13.5.

Its 50-day moving average was $12.7 and 200-day moving average was $9.11 The short ratio stood at 7.23 indicating a short percent outstanding of 0%.

Around 31.3% of the company’s stock are held by insiders while 7438.8% are held by institutions.